MeSH D009190 - myelodysplastic syndromes
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novast Laboratories | Decitabine | Decitabine | 2019-09-16 | |||
| Mylan | Azacitidine | Azacitidine Mylan | 2020-03-27 | |||
| Lenalidomide | Lenalidomide | 2022-08-30 | ||||
| Lenalidomide | Lenalidomide Mylan | 2020-12-18 | ||||
| Johnson & Johnson | Decitabine | Dacogen | 2012-09-20 | |||
| Cipla | Decitabine | Decitabine | 2017-11-16 | |||
| Lenalidomide | Lenalidomide | 2022-09-06 | ||||
| Lupin Research | Decitabine | Decitabine | 2018-11-09 | |||
| Sandoz | Decitabine | Decitabine | 2014-08-28 | |||
| Dr Reddys Laboratories | Decitabine | Decitabine | 2013-07-11 | |||
| Lenalidomide | Lenalidomide | 2021-10-14 | ||||
| Zydus Therapeutics | Decitabine | Decitabine | 2021-11-19 | |||
| Lenalidomide | Lenalidomide | 2022-09-12 | ||||
| Sun Pharmaceutical Industries | Decitabine | Decitabine | 2014-01-28 | |||
| Lenalidomide | Lenalidomide | 2023-02-08 | ||||
| Apotex | Lenalidomide | Lenalidomide | 2022-08-30 |
1
2
3
4
>
Clinical Trials
Historical Success Rate
Phase 1
75%187/248
Phase 2
35%90/255
Phase 3
21%26/122
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use